Navigation Links
Dutch Biotech Company Pepscan Appoints New CEO
Date:12/2/2009

LELYSTAD, The Netherlands, December 2 /PRNewswire/ -- Pepscan Holding NV, the Netherlands based biotechnology company focusing on protein mimicking technology for the generation of immune therapeutics today announced that it has appointed Wim E.M. Mol, Ph.D. as new Chief Executive Officer.

Dr. Mol will be responsible for all of Pepscans corporate functions and the overall management and strategic direction of the company. He brings to Pepscan more than 20 years of management experience in the international pharmaceutical industry.

Dr. Mol was previously at Schering Plough where he was Vice-President responsible for the global scientific development and commercial strategy of a Phase III project in an alliance with a subsidiary of Merck-Serono. Dr. Mol commented, "I look forward to working with the highly professional and talented team at Pepscan. It is exciting to contribute to the creation of new therapeutic antibodies against currently intractable targets, using manmade mimics of the biologically relevant part of the target".

"Dr. Mol has tremendous experience that will be very valuable to Pepscan. He has held multiple executive level roles, including general management positions in the USA and other countries, and executive director positions in global marketing and alliance management. With his track record as a result-driven leader, I am confident that he will bring Pepscan to the next level as a leading company in the field of protein mimicry, fully exploiting its proprietary CLIPS(TM) technology", said Wim Jongen, Chairman of the Board.

Joost van Bree Ph.D., who has been fully supportive of the change in business focus towards CLIPS based technology has decided to step down as CEO and continue to work on the development of therapeutic vaccines. Mr. Jongen said, "Joost has been instrumental in broadening the company portfolio and creating the momentum for growth. His contribution has been enormous and in this new phase of the company, he will continue to focus on the successful development of the proprietary pipeline of the therapeutic vaccine portfolio".

Notes to the editor:

About Pepscan

Pepscan Holding NV is a privately owned company based in Lelystad, the Netherlands. The company focuses on immunotherapy. It has developed a pipeline of therapeutic vaccine and antibody programs, of which the most advanced is in Phase II clinical testing. Pepscans proprietary CLIPS(TM) technology has been proven to yield functional antibodies reactive with a range of complex proteins, including GPCRs. For more information visit http://www.pepscan.com.

About CLIPS(TM) technology

CLIPS(TM) (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of complex protein domains and hitherto have been used in antibody and vaccine programs to create superior immunogens in the induction and selection of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins (e.g. GPCRs, ion channels, patented proteins).

SOURCE Pepscan Holding N.V.


'/>"/>
SOURCE Pepscan Holding N.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
2. Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers
3. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
4. Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
5. Cell Therapeutics Amends Modified Dutch Auction Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
6. Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market
7. Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes
8. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
11. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... and READING, England , May ... http://www.indegene.com ), a leading global provider of clinical, ... and healthcare organisations and TranScrip ( http://www.transcrip-partners.com ), ... throughout the product lifecycle, today announced the extension ... IntraScience.      (Logo: http://photos.prnewswire.com/prnh/20141208/720248 ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... cuvettes are used in leading laboratories all over the globe. Their cute firefly ... addition to manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never require ...
(Date:5/25/2016)... ... May 25, 2016 , ... The ... by the Office of the National Coordinator for Health IT (ONC) outlining a ... clinically relevant data were available when and where it was needed. The organization ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies ... will be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded a ... and tissue regeneration. , The novel method, developed by WPI faculty members Raymond ...
Breaking Biology Technology:
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
(Date:3/15/2016)... 2016 Yissum Research Development Company of ... of the Hebrew University, announced today the formation of ... of various human biological indicators. Neteera Technologies has completed ... private investors. ... of electromagnetic emissions from sweat ducts, enables reliable and ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):